within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX27_Capivasertib;

model Capivasertib
  extends Pharmacolibrary.Drugs.ATC.L.L01EX27;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Capivasertib is an oral, selective pan-AKT kinase inhibitor developed for the treatment of various cancers, including breast cancer. It is currently approved in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults who have received prior endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients after oral administration; values based on phase I/II clinical trials.</p><h4>References</h4><ol><li><p>Fernandez-Teruel, C, et al., &amp; Zhou, D (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. <i>Clinical pharmacokinetics</i> 63(8) 1191–1204. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01407-x&quot;>10.1007/s40262-024-01407-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39127854/&quot;>https://pubmed.ncbi.nlm.nih.gov/39127854</a></p></li><li><p>Miller, C, et al., &amp; Cullberg, M (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 94(2) 223–235. DOI:<a href=&quot;https://doi.org/10.1007/s00280-024-04667-3&quot;>10.1007/s00280-024-04667-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38643311/&quot;>https://pubmed.ncbi.nlm.nih.gov/38643311</a></p></li><li><p>Banerji, U, et al., &amp; Schellens, JHM (2018). A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in . <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 24(9) 2050–2059. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-17-2260&quot;>10.1158/1078-0432.CCR-17-2260</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29066505/&quot;>https://pubmed.ncbi.nlm.nih.gov/29066505</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Capivasertib;
